Efficacy of micafungin, a candin antifungal agent, in guinea pig models of disseminated candidiasis and pulmonary aspergillosis

• Published in: Japanese Journal of Chemotherapy Vol. 54; no. 3; pp. 255 - 259
• Main Authors: Nakai, Toru, Hatano, Kazuo, Wakai, Yoshimi, Matsumoto, Satoru, Maki, Katsuyuki, Ikeda, Fumiaki
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 2006; 公益社団法人 日本化学療法学会
• Subjects: animal model; Aspergillus fumigatus; Candida albicans; micafungin; voriconazole
• ISSN: 1340-7007; 1884-5886
• DOI: 10.11250/chemotherapy1995.54.255

The efficacy of micafungin (MCFG) and voriconazole (VRCZ) was evaluated in guinea pig models of disseminated candidiasis and pulmonary aspergillosis. MCFG and VRCZ were administered twice daily for 9 days starting at 2-4 hour after infection by subcutaneous injection and oral administration, respectively. MCFG and VRCZ significantly prolonged the survival of guinea pigs infected intravenously with Candida albicans at doses of 0.32 and 1mg/kg, respectively (p<0.05). MCFG and VRCZ significantly prolonged the survival of guinea pigs infected intratracheally with Aspergillus fumigatus at doses of 1.00 and 3.2mg/kg, respectively (p<0.01). These results supported the efficacy of clinical doses of MCFG and VRCZ in treating disseminated candidiasis and pulmonary aspergillosis.